Cosmetic cross-reference Noindex: medium evidence

112-75-4

CAS 112-75-4

112-75-4 (CAS 112-75-4) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral / FAERS
Adverse signals
0
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
112-75-4
CAS Number
112-75-4
UNII
5E4O85D8T2
InChIKey
SFBHPFQSSDCYSL-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1886777
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE ChEMBL 36 activities + assays 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 89.1 nM 1 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 112-75-4 used for in pharmaceutical contexts?

112-75-4 (CAS 112-75-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 112-75-4?

No adverse-event association or SIDER side-effect rows are rendered for 112-75-4 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 112-75-4 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Dimethyl Myristamine with EU status "restricted".

What clinical phase is 112-75-4 in?

No phase 1-4 clinical development badge is rendered for 112-75-4 because the matched compound identifier rows do not contain a max-phase value.